Longest Acting Proton Pump Inhibitors
Introduction to P-CABs and Traditional PPIs
- Potassium-competitive acid blockers (P-CABs), such as vonoprazan and tegoprazan, are the longest acting acid suppressants available, with half-lives of 6-9 hours, allowing them to maintain target intragastric pH levels for longer proportions of a 24-hour period, according to the American Gastroenterological Association 1, 2
- Standard PPIs, including omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole, have half-lives of 1-2 hours 1, 2
Pharmacokinetic Differences
- P-CABs have a half-life of 6-9 hours, providing prolonged gastric acid inhibition and maintaining target pH levels for extended periods throughout the 24-hour cycle, as recommended by the American Gastroenterological Association 1, 2
- Standard PPIs have a half-life of 1-2 hours, requiring more frequent dosing to maintain therapeutic levels 1, 2
Clinical Implications
- P-CABs achieve maximal acid suppression with once-daily dosing within 1 day, whereas traditional PPIs require 3-5 days to reach steady-state effectiveness, according to the American Gastroenterological Association 1, 2
- The American Gastroenterological Association recommends P-CABs primarily for PPI-refractory GERD, peptic ulcer disease, and H. pylori eradication therapy 1, 2
Relative Potency Among Traditional PPIs
- Rabeprazole 20 mg is equivalent to 36 mg omeprazole, as stated by the American College of Gastroenterology 3
- Esomeprazole 20 mg is equivalent to 32 mg omeprazole, according to the American College of Gastroenterology 3
- Pantoprazole 40 mg is equivalent to 9 mg omeprazole, making it the least potent option, as noted by the American College of Gastroenterology 3
Important Considerations
- Traditional PPIs require dosing 30-60 minutes before meals for optimal efficacy, whereas P-CABs can be taken independent of mealtimes due to their longer half-lives and acid stability, as recommended by the American Gastroenterological Association 1, 2
- Serum gastrin levels rise higher with P-CABs compared to PPIs and remain elevated throughout treatment duration, though long-term safety data show comparable adverse event profiles, according to the American Gastroenterological Association 1, 2